ФАМЦИКЛОВИР В ЛЕЧЕНИИ ГЕРПЕСВИРУСНЫХ ИНФЕКЦИЙ: НОВЫЕ И ЗАБЫТЫЕ СТРАНИЦЫ

DOI: https://doi.org/10.29296/25877305-2019-02-13
Скачать статью в PDF
Номер журнала: 
2
Год издания: 
2019

А. Игнатовский, кандидат медицинских наук Санкт-Петербургский государственный университет E-mail: derm@list.ru

Рассмотрены особенности фармакокинетики и фармакодинамики фамцикловира при лечении герпесвирусных инфекций. Продемонстрирована его высокая эффективность, особенно при лечении проявлений герпесвирусных инфекций, сопровождающихся такими неврологическими симптомами, как боль. Описана эффективность фамцикловира при назначении короткими курсами, что повышает приверженность пациентов лечению и позволяет начать его в максимально ранние сроки.
Ключевые слова: 
фармакология
инфекционные болезни
опоясывающий герпес
фамцикловир
простой герпес
генитальный герпес
супрессивная терапия
Для цитирования
Игнатовский А. ФАМЦИКЛОВИР В ЛЕЧЕНИИ ГЕРПЕСВИРУСНЫХ ИНФЕКЦИЙ: НОВЫЕ И ЗАБЫТЫЕ СТРАНИЦЫ . Врач, 2019; (2): 67-75 https://doi.org/10.29296/25877305-2019-02-13

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Федеральные клинические рекомендации по дерматовенерологии. Российское общество дерматовенерологов и косметологов / М., 2015; с. 655 [Federal'nye klinicheskie rekomendatsii po dermatovenerologii. Rossiiskoe obshchestvo dermatovenerologov i kosmetologov / M., 2015; s. 655 (in Russ.)].
  2. Галегов Г.А. Лекарственная терапия герпес-вирусной инфекции: фундаментальные аспекты и современные клинические достижения // Consilium medicum. – 2002; 4 (5): 240–3 [Galegov G.A. Lekarstvennaya terapiya gerpes-virusnoi infektsii: fundamental'nye aspekty i sovremennye klinicheskie dostizheniya // Consilium medicum. – 2002; 4 (5): 240–3 (in Russ.)].
  3. Bacon T., Boyd M. Activiti of penciclovir against Epstein-Barr virus // Antimicrob. Agents Chemother. – 1995; 39: 1599–602.
  4. Shen H., Alsatie M., Ecker G. et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection // Clin. Gastroenterol. Hepatol. – 2004; 2: 330–6.
  5. Vere Hodge, R., Cheng Y.-C. The mode of action of penciclovir // Antiviral Chem. Chemother. – 1993; 4 (Suppl. 1): 13–24.
  6. Vere Hodge R., Perkins R. Mode of action of 9-(40hydroxy-3-hydroxymethylbut-1-yl0guanine (BRL 39123) against herpes simplex virus in MRC-5 cells // Antimicrob. Agents Chemother. – 1989; 33: 223–9.
  7. Weinberg A., Bate B., Masters H. et al. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2 // Antimicrob. Agents Chemother. – 1992; 36: 2037–8.
  8. Earnshaw D., Bacon T., Darlison S. et al. Penciclovir mode of action studies in HSV – I. HSV – 2 and VZV infected MRC – 5 cells, providing a rationale for its persistent antiviral activity // Antimicrob Agents Chemother. – 1992; 36: 2747–57.
  9. Degreef H., Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients // Int. J. Antimicrob Agents. – 1994; 4: 241–6.
  10. Bacon T., Levin M. et al. Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy // Clin. Microbiol. Rev. – 2003; 16 (1): 114–28.
  11. Spruance S., Bodsworth N. Single-dose, patient-initiated famciclovir: A randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis // J. Am. Acad. Dermatol. – 2006; 55 (1): 47–53.
  12. Diaz–Mitoma F. et al. Oral famciclovir for the supression of recurrent genital herpes: a randomized controlled trial // JAMA. – 1998; 280: 887–92.
  13. Saks S. et al. Patient–initiated, twice–daily oral famciclovir for early recurrent genital herpes: a randomized double–blind multicenter trial // JAMA. – 1996; 276: 44–9.
  14. Масюкова С.А, Владимирова Е.В., Фамцикловир в лечении герпетических инфекций // Русский медицинский журнал. – 2001; 9 (11): 444–6 [Masyukova S.A, Vladimirova E.V., Famtsiklovir v lechenii gerpeticheskikh infektsii // Russkii meditsinskii zhurnal. – 2001; 9 (11): 444–6 (in Russ.)].
  15. Cernik C., Gallina K., Brodell R. The treatment of herpes simplex infections: an evidence-based review // Arch. Intern. Med. – 2008; 168 (11): 1137–44.
  16. Aoki F., Tyring S., Diaz-Mitoma F. et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial // Clin. Infect. Dis. – 2006; 42: 8–13.
  17. Sacks S., Aoki F., Diaz-Mitoma F. et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. Division of Infectious Diseases, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Canada // JAMA. – 1996; 276 (1): 44–9.
  18. Engel Y. Long-term suppression of Genital Herpes // JAMA. – 1998; 280 (10): 928–9.
  19. Mertz G., Loveless M., Levin M. et al. Oral famciclovir for suppression of recurrent genital he pes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial // Arch. Intern. Med. – 1997; 157 (3): 343–9.
  20. Diaz-Mitoma F., Sibbald R., Shafran S. et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial // JAMA. – 1998; 280 (10): 887–92.
  21. Tyring S., Berger T., Yen-Moore A. et al. Single-day therapy for recurrent genital herpes // Am. J. Clin. Dermatol. – 2006; 7: 209–11.
  22. Mattison H., Reichman R., Benedetti J. et al. Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes // Am. J. Med. – 1988; 85 (2A): 20–5.
  23. Kerob D., Assier-Bonnet H., Esnault-Gelly P. et al. Recurrent erythema multiforme unresponsive to acyclovir prophylaxis and responsive to valacyclovir continuous therapy // Arch. Dermatol. – 1998; 134 (7): 876–7.
  24. Olson J., Robles D., Kirby P. et al. Kaposi varicelliform eruption (eczema herpeticum) // Dermatol. Online J. – 2008; 14 (2): 18. http://dermatology.cdlib.org/142/case_presentations/eczemaherp/olson.html/
  25. Schacker T., Hu H., Koelle D. et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial // Ann. Intern. Med. – 1998; 128 (1): 21–8.
  26. Gross G. Herpes – simplex – Virus und Varicella – Zoster – Virus – Infektionen // “Dermatologie, heutiger Stand”, Stuttgart – New-York: Georg Thieme Verlag, 1995; p. 43–50.
  27. Degreef H. Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients // Int. J. Antimicrob. Agents. – 1994; 4: 241–6.
  28. Tyring S., Barbaras R., Nahlik J. et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial // Ann. Intern. Med. – 1995; 123: 89–96.
  29. Tyring S. Advances in the Treatment of Herpesvirus Infection: The Role of Famciclovir // Clin. Therapeutics. – 1998; 20 (4): 661–71.
  30. Fumitake Ono, Shinichiro Yasumoto, Minao Furumura et al.,Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster // J. Dermatol. – 2012; 39: 902–8.
  31. Tyring S., Beutner K., Tucker B. et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older // Arch. Fam. Med. – 2000; 9: 863–9.